Projecting ESRD Incidence and Prevalence in the United States through 2030

被引:226
|
作者
McCullough, Keith P. [1 ,2 ]
Morgenstern, Hal [2 ,3 ,4 ]
Saran, Rajiv [2 ,5 ,7 ]
Herman, William H. [2 ,5 ]
Robinson, Bruce M. [1 ,6 ]
机构
[1] Arbor Res Collaborat Hlth, 340 East Huron,Suite 300, Ann Arbor, MI 48104 USA
[2] Univ Michigan, Dept Epidemiol, Ann Arbor, MI 48109 USA
[3] Univ Michigan, Sch Publ Hlth, Dept Environm Hlth Sci, Ann Arbor, MI 48109 USA
[4] Univ Michigan, Sch Med, Dept Urol, Ann Arbor, MI USA
[5] Univ Michigan, Div Endocrinol Diabet & Metab, Ann Arbor, MI 48109 USA
[6] Univ Michigan, Dept Internal Med, Div Nephrol, Ann Arbor, MI 48109 USA
[7] Univ Michigan, Dept Internal Med, Div Nephrol, Kidney Epidemiol & Cost Ctr, Ann Arbor, MI 48109 USA
来源
基金
美国国家卫生研究院;
关键词
STAGE RENAL-DISEASE; DIALYSIS; NUMBER; OBESITY; TRENDS;
D O I
10.1681/ASN.2018050531
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background Population rates of obesity, hypertension, diabetes, age, and race can be used in simulation models to develop projections of ESRD incidence and prevalence. Such projections can inform long-range planning for ESRD resources needs. Methods We used an open compartmental simulation model to estimate the incidence and prevalence of ESRD in the United States through 2030 on the basis of wide-ranging projections of population obesity and ESRD death rates. Population trends in age, race, hypertension, and diabetes were on the basis of data from the Centers for Disease Control and Prevention's National Health and Nutrition Examination Survey and the US Census. Results The increase in ESRD incidence rates within age and race groups has leveled off and/or declined in recent years, but our model indicates that population changes in age and race distribution, obesity and diabetes prevalence, and ESRD survival will result in a 11%-18% increase in the crude incidence rate from 2015 to 2030. This incidence trend along with reductions in ESRD mortality will increase the number of patients with ESRD by 29%-68% during the same period to between 971,000 and 1,259,000 in 2030. Conclusions The burden of ESRD will increase in the United States population through 2030 due to demographic, clinical, and lifestyle shifts in the population and improvements in RRT. Planning for ESRD resource allocation should allow for substantial continued growth in the population of patients with ESRD. Future interventions should be directed to preventing the progression of CKD to kidney failure.
引用
收藏
页码:127 / 135
页数:9
相关论文
共 50 条
  • [1] Projecting the United States ESRD population: Issues regarding treatment of patients with ESRD
    Szczech, LA
    Lazar, IL
    [J]. KIDNEY INTERNATIONAL, 2004, 66 : S3 - S7
  • [2] Projecting the US ESRD population to 2030.
    Gilbertson, DT
    Solid, CA
    Xue, JL
    Collins, AJ
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2003, 14 : 255A - 255A
  • [3] Future of Hepatocellular Carcinoma Incidence in the United States Forecast Through 2030
    Petrick, Jessica L.
    Kelly, Scott P.
    Altekruse, Sean F.
    McGlynn, Katherine A.
    Rosenberg, Philip S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15) : 1787 - +
  • [4] Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States
    Rahib, Lola
    Smith, Benjamin D.
    Aizenberg, Rhonda
    Rosenzweig, Allison B.
    Fleshman, Julie M.
    Matrisian, Lynn M.
    [J]. CANCER RESEARCH, 2014, 74 (11) : 2913 - 2921
  • [5] Projecting incidence and costs of sprawl in the united states
    Burchell, RW
    Galley, CC
    [J]. TRAVEL DEMAND AND LAND USE 2003: PLANNING AND ADMINISTRATION, 2003, (1831): : 150 - 157
  • [6] Incidence & prevalence of ESRD
    不详
    [J]. AMERICAN JOURNAL OF KIDNEY DISEASES, 2001, 38 (04) : S37 - S52
  • [7] Ovarian cancer incidence projections in the United States: Expected increases through 2030.
    Stewart, Sherri L.
    Thompson, Trevor D.
    Weir, Hannah K.
    Rim, Sun Hee
    [J]. CLINICAL CANCER RESEARCH, 2016, 22
  • [8] Projecting the Prevalence and Costs of Metastatic Breast Cancer From 2015 through 2030
    Gogate, Anagha
    Wheeler, Stephanie B.
    Reeder-Hayes, Katherine E.
    Ekwueme, Donatus U.
    Fairley, Temeika L.
    Drier, Sarah
    Trogdon, Justin G.
    [J]. JNCI CANCER SPECTRUM, 2021, 5 (04)
  • [9] Projections of cancer incidence and burden among the HIV-positive population in the United States through 2030
    Islam, Jessica Y.
    Rosenberg, Philip S.
    Hall, H. Irene
    Jacobson, Evin U.
    Engels, Eric A.
    Shiels, Meredith S.
    [J]. CANCER RESEARCH, 2017, 77
  • [10] The forecasted prevalence of comorbidities and multimorbidity in people with HIV in the United States through the year 2030: A modeling study
    Althoff, Keri N.
    Stewart, Cameron
    Humes, Elizabeth
    Gerace, Lucas
    Boyd, Cynthia
    Gebo, Kelly
    Justice, Amy C.
    Hyle, Emily P.
    Coburn, Sally B.
    Lang, Raynell
    Silverberg, Michael J.
    Horberg, Michael A.
    Lima, Viviane D.
    Gill, M. John
    Karris, Maile
    Rebeiro, Peter F.
    Thorne, Jennifer
    Rich, Ashleigh J.
    Crane, Heidi
    Kitahata, Mari
    Rubtsova, Anna
    Wong, Cherise
    Leng, Sean
    Marconi, Vincent C.
    D'Souza, Gypsyamber
    Kim, Hyang Nina
    Napravnik, Sonia
    Mcginnis, Kathleen
    Kirk, Gregory D.
    Sterling, Timothy R.
    Moore, Richard D.
    Kasaie, Parastu
    Dodd, Philippa C.
    Dodd, Philippa C.
    Dodd, Philippa C.
    Dodd, Philippa C.
    Dodd, Philippa C.
    [J]. PLOS MEDICINE, 2024, 21 (01)